Current trials for frontline therapy of mantle cell lymphoma.

about

Identification of MMP9 as a novel key gene in mantle cell lymphoma based on bioinformatic analysis and design of cyclic peptides as MMP9 inhibitors based on molecular docking

P2860

Q57130683-1AB27B36-6C83-494E-B2EB-4ACA0DD64217

P2860

Current trials for frontline therapy of mantle cell lymphoma.

Item

http://www.wikidata.org/entity/Q49279565

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Current trials for frontline therapy of mantle cell lymphoma.

@en

Current trials for frontline therapy of mantle cell lymphoma.

@nl

type

Item

label

Current trials for frontline therapy of mantle cell lymphoma.

@en

Current trials for frontline therapy of mantle cell lymphoma.

@nl

prefLabel

Current trials for frontline therapy of mantle cell lymphoma.

@en

Current trials for frontline therapy of mantle cell lymphoma.

@nl

P1476

Current trials for frontline therapy of mantle cell lymphoma.

@en

P2093

Jorge Romaguera

http://www.w3.org/2001/XMLSchema#string

Michael Wang

http://www.w3.org/2001/XMLSchema#string

Raphael E Steiner

http://www.w3.org/2001/XMLSchema#string

P2860

SOX11 is a biomarker for cyclin D1-negative mantle cell lymphoma

Mantle cell lymphoma: evolving management strategies

Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor

Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Mantle Cell Lymphoma: Is It Time for a New Treatment Paradigm?

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

P2888

s13045-018-0556-x

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13045-018-0556-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1100680002

http://www.w3.org/2001/XMLSchema#string

P698

29374487

http://www.w3.org/2001/XMLSchema#string

P932

5787314

http://www.w3.org/2001/XMLSchema#string

Current trials for frontline therapy of mantle cell lymphoma.

about

P2860

P2860

Current trials for frontline therapy of mantle cell lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P932